FamiCord Advances Scientific Dialogue on Cell Therapies at EACD 2026

FamiCord Group participated in the 38th Annual Meeting of the European Academy of Childhood-onset Disability (EACD), held on 3–6 June 2026 in Galway, Ireland, reaffirming its commitment to advancing evidence-based regenerative medicine and supporting scientific collaboration in the field of pediatric neurology.

As Europe’s leading scientific congress dedicated to childhood-onset disabilities, EACD 2026 brought together clinicians, researchers and healthcare professionals from around the world to discuss the latest developments in the diagnosis and treatment of neurological disorders in children. This year’s scientific programme reflected the growing international interest in regenerative medicine, with dedicated sessions focusing on the role of umbilical cord blood and perinatal tissue-derived cell therapies in cerebral palsy.

FamiCord Industry Symposium

As part of the congress, FamiCord organized an Industry Symposium entitled “Status of Perinatal Tissue-Derived Stem Cells in Cerebral Palsy: Challenges and Opportunities”, moderated by Professor Marcin Bonikowski.

The symposium featured internationally recognized experts Professor Iona Novak (Cerebral Palsy Alliance, Australia) and Professor Jeroen Vermeulen (Maastricht University Medical Center, the Netherlands), who reviewed the current clinical evidence supporting the use of umbilical cord blood and mesenchymal stromal cells (MSCs) in cerebral palsy. Both speakers emphasized the encouraging safety profile of cell-based therapies while highlighting the importance of further high-quality clinical research to strengthen the evidence base and support broader clinical implementation.

Presenting New Clinical Data

During the congress, FamiCord also co-authored and presented a scientific poster together with the University Children’s Hospital in Lublin entitled “Mesenchymal Stem Cell Therapy Improves Motor Function in Children with Cerebral Palsy: Preliminary Independent Observations.”

The study presented preliminary clinical observations from children treated with GMP-manufactured mesenchymal stromal cells produced as an ATMP under the Hospital Exemption pathway. Importantly, treatment outcomes were assessed independently by a clinical centre different from the treating institution, providing additional scientific value to the presented data. Preliminary findings demonstrated improvements in motor function in the majority of evaluated patients using standardized neurological assessment scales.

Advancing Evidence-Based Regenerative Medicine

EACD 2026 confirmed the growing scientific interest in regenerative medicine for neurological disorders. Throughout the congress, experts discussed the biological rationale for cell therapies, the role of neuroinflammation in cerebral palsy, encouraging clinical safety data and the need for further Phase III clinical trials to establish future standards of care.

“Scientific progress is driven by collaboration, high-quality clinical evidence and open dialogue. EACD provides a unique platform to exchange knowledge with leading experts in pediatric neurology and regenerative medicine. At FamiCord, we are proud to contribute not only through scientific research and clinical collaborations, but also by creating opportunities for meaningful discussion that helps translate promising science into future therapeutic solutions for patients,” said Tomasz Baran, Chief Medical Officer of FamiCord Group.

More Than a Stem Cell Bank

FamiCord’s presence at EACD 2026 reflects the Group’s long-term strategy of supporting the development of advanced cell therapies through scientific partnerships, translational research and GMP manufacturing capabilities.

By organizing an international scientific symposium, presenting original clinical data and actively contributing to discussions on the future of regenerative medicine, FamiCord continues to strengthen its position as more than a stem cell bank—a trusted partner in the development of advanced therapy medicinal products (ATMPs) and innovative cell-based therapies.